 | |
| Company type | Public |
|---|---|
| Nasdaq: MNKD Russell 2000 Component | |
| Industry | Biotechnology |
| Founded | 1991 |
| Founder | Alfred E. Mann |
| Headquarters | , U.S. |
Key people | Kent Kresa (chairman) Dr. Michael E. Castagna (CEO) |
| Revenue |  US$63.038 million (2019)[1] |
 −US$44.597 million (2019)[1] | |
| −US$51.903 million (2019)[1] | |
| Total assets |  $93.725 million (2019)[1] |
| Total equity | $284.252 million (2019)[1] |
Number of employees | 233 (2019)[1] |
| Website | mannkindcorp |
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
MannKind Corporation was named after its founder, Alfred E. Mann.